Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
Response to authors re commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs.
Henry D, Stehlik P, Rosella L.
Int J Epidemiol. 2018 Apr 1;47(2):675-676. doi: 10.1093/ije/dyy051. No abstract available.
Similar articles
Authors' reply to commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs.
Brophy JM, Bally M.
Int J Epidemiol. 2018 Apr 1;47(2):674-675. doi: 10.1093/ije/dyy050. No abstract available.
Commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs.
Stehlik P, Rosella L, Henry D.
Int J Epidemiol. 2018 Apr 1;47(2):362-367. doi: 10.1093/ije/dyx284. No abstract available.
[Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous].
Horváth VJ, Tabák GÁ, Szabó G, Putz Z, Koós CG, Lakatos P.
Orv Hetil. 2015 Mar 29;156(13):516-20. doi: 10.1556/OH.2015.30120. Review. Hungarian.
[Non steroidal anti-inflammatory drugs (NSAIDs) - balancing gastrointestinal complications and the cardiovascular risk].
Kandulski A, Venerito M, Malfertheiner P.
Dtsch Med Wochenschr. 2009 Aug;134(33):1635-40; quiz 1641-4. doi: 10.1055/s-0029-1233993. Epub 2009 Jul 31. Review. German.
Non-steroidal anti-inflammatory drugs and cardiovascular risk--a rheumatologist's.
Whitelaw D.
S Afr Med J. 2007 Dec;97(12):1230. No abstract available.
Do non-steroidal anti-inflammatory drugs increase or decrease cardiovascular risk in patients with rheumatoid arthritis?
Sfikakis PP, Bournia VK, Kitas G.
Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 87):S-8-9. Epub 2014 Oct 20. No abstract available.
Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.
Zingler G, Hermann B, Fischer T, Herdegen T.
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1479-1492. doi: 10.1080/17512433.2016.1230495. Epub 2016 Sep 8. Review.
Non-steroidal anti-inflammatory drugs and cardiovascular risk.
Allwood B, Blockman M.
S Afr Med J. 2008 Jan;98(1):9-10. No abstract available.
Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy.
Russell RI.
Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S14-8. Review.
Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
Hermann M, Ruschitzka F.
Ann Med. 2007;39(1):18-27. Review.
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.
Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P.
BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086. Review.
Chin A, Commerford P.
S Afr Med J. 2007 Jul;97(7):500-3. Review. No abstract available.
Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
Woodruff T.
Intern Med J. 2006 Dec;36(12):797-8; author reply 798-9. No abstract available.
Cardiovascular hazard and non-steroidal anti-inflammatory drugs.
Wang D, Wang M, Cheng Y, Fitzgerald GA.
Curr Opin Pharmacol. 2005 Apr;5(2):204-10. Review. Erratum in: Curr Opin Pharmacol. 2005 Oct;5(5):556. Wong, Dairong [corrected to Wang, Dairong].
Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints.
Koffeman AR, Valkhoff VE, Jong GW, Warlé-van Herwaarden MF, Bindels PJ, Sturkenboom MC, Luijsterburg PA, Bierma-Zeinstra SM.
Scand J Prim Health Care. 2014 Jun;32(2):90-8. doi: 10.3109/02813432.2014.929810. Epub 2014 Jun 15.
[Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
Jukić A, Kaliterna DM, Radić M.
Reumatizam. 2010;57(1):26-8. Review. Croatian.
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.
Fosbøl EL, Køber L, Torp-Pedersen C, Gislason GH.
Expert Opin Drug Saf. 2010 Nov;9(6):893-903. doi: 10.1517/14740338.2010.501331. Review.
Hot Topics in Primary Care: Nonsteroidal Anti- inflammatory Drugs and Cardiovascular Risk: Where Are We Today?
Ruoff G.
J Fam Pract. 2015 Dec;64(12 Suppl):S67-70. Review. No abstract available.
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V.
Lancet. 2007 Dec 22;370(9605):2138-51. Review.
Filters: Manage Filters